OS Therapies (OSTX) Shares Outstanding (2023 - 2026)
OS Therapies' (OSTX) quarterly Shares Outstanding (Entity) came in at $12.6 million in Q1 2026, down 40.94% YoY from $21.3 million in Q1 2025, and up 22.2% on a QoQ basis from $10.3 million in Q4 2025.
OS Therapies (OSTX) Shares Outstanding (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Shares Outstanding (Entity) data on file, last reported at $12.6 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 40.94% year-over-year to $12.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 million (down 40.94% YoY) and the FY2025 annual result came in at $10.3 million, down 16.64% from the prior year.
- Shares Outstanding (Entity) climbed to $12.6 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $21.3 million in Q1 2025 to a low of $1.8 million in Q3 2025.
- A 4-year average of $8.6 million and a median of $6.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 256.32% in 2025, down 88.83% in 2025.
- Tracing OSTX's Shares Outstanding (Entity) over 4 years: stood at $5.3 million in 2023, then jumped by 131.78% to $12.4 million in 2024, then slipped by 16.64% to $10.3 million in 2025, then increased by 22.2% to $12.6 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $12.6 million (Q1 2026), $10.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.61 Mn |
| Dec 31, 2025 | 10.32 Mn |
| Sep 30, 2025 | 1.78 Mn |
| Jun 30, 2025 | 4.77 Mn |
| Mar 31, 2025 | 12.38 Mn |
| Dec 31, 2024 | 12.38 Mn |
| Sep 30, 2024 | 15.90 Mn |
| Jun 30, 2024 | 5.99 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 5.43 Mn |
| Sep 30, 2023 | 5.34 Mn |
| Jun 30, 2023 | 5.34 Mn |
| Mar 31, 2023 | 5.11 Mn |